Abstract 3840: ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy
Abstract
The clinical potential of epigenetic cancer therapy has not been fully realized. Histone deacetylase inhibitors (HDACi), for example, only benefit a minor fraction of all cancer patients despite thousands of preclinical studies demonstrating their antitumor effects. In this study we show that a new structural class of protein disulfide isomerase (PDI) that was discovered by our lab dramatically enhances the antitumor effects of HDACi and select...
Paper Details
Title
Abstract 3840: ATF3 drives synergy between protein disulfide isomerase (PDI) inhibitors and epigenetic cancer therapy
Published Date
Jul 1, 2019
Journal
Volume
79
Pages
3840 - 3840
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History